Analysis of Long-term (Investment) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Edwards Lifesciences Corp., long-term (investment) activity ratios
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Edwards Lifesciences Corp. net fixed asset turnover ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Edwards Lifesciences Corp. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Edwards Lifesciences Corp. total asset turnover ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Edwards Lifesciences Corp. equity turnover ratio deteriorated from 2019 to 2020 and from 2020 to 2021. |
Net Fixed Asset Turnover
Edwards Lifesciences Corp., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net sales | 5,232,500) | 4,386,300) | 4,348,000) | 3,722,800) | 3,435,300) | |
| Property, plant, and equipment, net | 1,546,600) | 1,395,200) | 1,060,300) | 867,500) | 679,700) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 3.38 | 3.14 | 4.10 | 4.29 | 5.05 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| Abbott Laboratories | 4.81 | 3.83 | 3.97 | — | — | |
| Cigna Group | 46.73 | 37.85 | 34.45 | — | — | |
| CVS Health Corp. | 22.56 | 21.25 | 21.24 | — | — | |
| Elevance Health Inc. | 34.94 | 34.69 | 32.92 | — | — | |
| Intuitive Surgical Inc. | 3.04 | 2.76 | 3.52 | — | — | |
| Medtronic PLC | 5.77 | 5.99 | 6.54 | — | — | |
| UnitedHealth Group Inc. | 31.81 | 29.64 | 27.60 | — | — | |
| Net Fixed Asset Turnover, Sector | ||||||
| Health Care Equipment & Services | 21.18 | 19.65 | — | — | — | |
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | 10.03 | 9.23 | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Net fixed asset turnover = Net sales ÷ Property, plant, and equipment, net
= 5,232,500 ÷ 1,546,600 = 3.38
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Edwards Lifesciences Corp. net fixed asset turnover ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Edwards Lifesciences Corp., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net sales | 5,232,500) | 4,386,300) | 4,348,000) | 3,722,800) | 3,435,300) | |
| Property, plant, and equipment, net | 1,546,600) | 1,395,200) | 1,060,300) | 867,500) | 679,700) | |
| Operating lease right-of-use assets | 92,100) | 94,200) | 80,100) | —) | —) | |
| Property, plant, and equipment, net (including operating lease, right-of-use asset) | 1,638,700) | 1,489,400) | 1,140,400) | 867,500) | 679,700) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 3.19 | 2.95 | 3.81 | 4.29 | 5.05 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| Abbott Laboratories | 4.26 | 3.42 | 3.56 | — | — | |
| Cigna Group | 41.37 | 33.46 | 30.72 | — | — | |
| CVS Health Corp. | 9.09 | 8.04 | 7.77 | — | — | |
| Elevance Health Inc. | 30.12 | 29.26 | 27.82 | — | — | |
| Intuitive Surgical Inc. | 2.93 | 2.66 | 3.32 | — | — | |
| Medtronic PLC | 4.84 | 5.02 | 6.54 | — | — | |
| UnitedHealth Group Inc. | 21.54 | 19.55 | 18.97 | — | — | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector | ||||||
| Health Care Equipment & Services | 13.35 | 11.97 | — | — | — | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry | ||||||
| Health Care | 7.94 | 7.23 | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Net sales ÷ Property, plant, and equipment, net (including operating lease, right-of-use asset)
= 5,232,500 ÷ 1,638,700 = 3.19
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Edwards Lifesciences Corp. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Total Asset Turnover
Edwards Lifesciences Corp., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net sales | 5,232,500) | 4,386,300) | 4,348,000) | 3,722,800) | 3,435,300) | |
| Total assets | 8,502,600) | 7,237,100) | 6,488,100) | 5,323,700) | 5,695,800) | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.62 | 0.61 | 0.67 | 0.70 | 0.60 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| Abbott Laboratories | 0.57 | 0.48 | 0.47 | — | — | |
| Cigna Group | 1.11 | 1.02 | 0.98 | — | — | |
| CVS Health Corp. | 1.25 | 1.16 | 1.15 | — | — | |
| Elevance Health Inc. | 1.41 | 1.39 | 1.33 | — | — | |
| Intuitive Surgical Inc. | 0.42 | 0.39 | 0.46 | — | — | |
| Medtronic PLC | 0.32 | 0.32 | 0.34 | — | — | |
| UnitedHealth Group Inc. | 1.34 | 1.30 | 1.38 | — | — | |
| Total Asset Turnover, Sector | ||||||
| Health Care Equipment & Services | 1.10 | 1.03 | — | — | — | |
| Total Asset Turnover, Industry | ||||||
| Health Care | 0.73 | 0.68 | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Total asset turnover = Net sales ÷ Total assets
= 5,232,500 ÷ 8,502,600 = 0.62
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Edwards Lifesciences Corp. total asset turnover ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Equity Turnover
Edwards Lifesciences Corp., equity turnover calculation, comparison to benchmarks
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net sales | 5,232,500) | 4,386,300) | 4,348,000) | 3,722,800) | 3,435,300) | |
| Stockholders’ equity | 5,835,900) | 4,574,300) | 4,148,300) | 3,140,400) | 2,956,200) | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 0.90 | 0.96 | 1.05 | 1.19 | 1.16 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| Abbott Laboratories | 1.20 | 1.06 | 1.03 | — | — | |
| Cigna Group | 3.66 | 3.16 | 3.36 | — | — | |
| CVS Health Corp. | 3.87 | 3.86 | 4.00 | — | — | |
| Elevance Health Inc. | 3.80 | 3.64 | 3.25 | — | — | |
| Intuitive Surgical Inc. | 0.48 | 0.45 | 0.54 | — | — | |
| Medtronic PLC | 0.59 | 0.57 | 0.61 | — | — | |
| UnitedHealth Group Inc. | 3.98 | 3.90 | 4.17 | — | — | |
| Equity Turnover, Sector | ||||||
| Health Care Equipment & Services | 2.93 | 2.80 | — | — | — | |
| Equity Turnover, Industry | ||||||
| Health Care | 2.03 | 1.99 | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Equity turnover = Net sales ÷ Stockholders’ equity
= 5,232,500 ÷ 5,835,900 = 0.90
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Edwards Lifesciences Corp. equity turnover ratio deteriorated from 2019 to 2020 and from 2020 to 2021. |